SING IMT™

About Samsara Vision

Samsara Vision is a U.S.-based medical device company targeting the high-unmet need of late-stage age-related macular degeneration (AMD), the leading cause of blindness in older Americans. Its core asset is the first and only FDA-approved implantable telescope (IMT) designed to improve central vision. With a commercially approved product in the U.S. and Europe and a next-generation device (SING IMT) in a pivotal U.S. trial, the company is positioned to expand its addressable patient population and improve surgical adoption. Leadership includes seasoned ophthalmology commercial and financial executives from Johnson & Johnson, Alcon, and investment banking.

Therapeutic Areas

Other Late-Stage Age-Related Macular Degeneration (AMD) Drugs